Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Natasha Viglianti"'
Autor:
Fabiola Cecchi, Natasha Viglianti, Marlon Rebelatto, Norah J Shire, Simon T Barry, Tsveta Milenkova, Elizabeth Croydon, Danielle Carroll, J Carl Barrett
Publikováno v:
Journal of Clinical Oncology. 41:194-194
194 Background: Although regularly used in breast and gastric cancer, HER2 testing is not routinely performed in colorectal cancer (CRC). Immunohistochemistry (IHC) and in situ hybridization (ISH) scoring have not been optimized for assessment of HER
Autor:
David Planchard, Julie R. Brahmer, James C. Yang, Yuh-Min Chen, Kang-Yun Lee, Thatthan Suksombooncharoen, Natasha Viglianti, Mark Gustavson, Alejandra Ragone, Amaya Gasco Hernandez
Publikováno v:
Cancer Research. 82:CT572-CT572
Background: HER2 overexpression is an established molecular target in breast and gastric cancer therapy, but no HER2-targeted therapies are currently available for NSCLC. In studies of NSCLC and lung cancer overall, the prevalence of HER2 overexpress
Autor:
Bob T. Li, Myung-Ju Ahn, Koichi Goto, Julien Mazieres, Sukhmani Kaur Padda, William Nassib William, Yi-Long Wu, Simon Dearden, Alejandra Ragone, Natasha Viglianti, Amaya Gasco
Publikováno v:
Journal of Clinical Oncology. 40:TPS9137-TPS9137
TPS9137 Background: The standard of care (SOC) for patients with oncogene driver subsets of metastatic NSCLC is guided by specific molecular characterization and includes immunotherapy, chemoimmunotherapy, and matched targeted therapies. Although tar
Publikováno v:
Journal of Clinical Oncology. 39:TPS261-TPS261
TPS261 Background: For patients (pts) with HER2-overexpressing metastatic gastric cancer, trastuzumab + chemotherapy is a standard first-line option but provides only a modest overall survival (OS) benefit vs chemotherapy. T-DXd is an antibody-drug c